Infant Bacterial Therapeutics AB
http://ibtherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Infant Bacterial Therapeutics AB
European Firms Adapting To Coronavirus Challenges
Companies across Europe are dealing with new challenges stemming from the coronavirus outbreak, particularly with supply issues due to increased demand. This article details the responses of five consumer health players in the region: Reckitt Benckiser, Zentiva, Vitabiotics, Alliance Pharma and BioGaia.
Infant Bacterial Therapeutics Harnesses Microbiome To Treat Preterm Babies
By harvesting Lactobacillus reuteri from lactating mothers, Infant Bacterial Therapeutics has developed an approach to treat necrotizing enterocolitis, a major killer of premature babies.
Deals Shaping The Medical Industry, April 2014
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February through March 2014.
Start-Up Quarterly Statistics, Q3 2011
Biopharma start-ups raised $299 million and just over half were Series A rounds. Device companies brought in $134 million, while two diagnostics firms raised $10 million total. Ophthalmology was the most popular theracat for biopharma alliances. Just one acquisition involving a start-up took place.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- BioGaia
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice